Please login to the form below

Not currently logged in


This page shows the latest Quad news and features for those working in and with pharma, biotech and healthcare.

ViiV takes two-drug cocktail for first-line HIV into phase III

ViiV takes two-drug cocktail for first-line HIV into phase III

HIV therapies that combine multiple drugs into one tablet such as ViiV's Triumeq (dolutegravir/abacavir/lamivudine) and Gilead's Quad product (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) are expected to be

Latest news

  • Aurobindo joins Patent Pool

    Quad (a combination of the three drugs and tenofovir).

  • Gilead agrees HIV patent pool deal

    as a combination pill to be called Quad.

  • Gilead's HIV drug meets phase III endpoint

    Gilead is studying the use of elvitegravir as part of a separate investigational fixed-dose, single-tablet "Quad" regimen. ... Quad pill," said Dr Norbert Bischofberger, executive vice president, R&D and chief scientific officer, Gilead Sciences. .

  • A competitive edge

    An exciting new four-in-one fixed-dose tablet, known as "Quad", has been developed by Gilead Sciences. ... CROI. These results demonstrated that the Quad regimen exhibited antiretroviral activity comparable to that of Atripla.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Cegedim Health Data

Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...

Latest intelligence

Box 1
Strategic commitment
KOL Ambassador Program & Podcast Creation: A Customer Story
Animation: Living With
The journey from the patient's perspective...